Literature DB >> 8132366

Effect of ceftibuten on the normal intestinal microflora.

B Brismar1, C Edlund, C E Nord.   

Abstract

14 healthy volunteers were given 400 mg ceftibuten orally once daily for ten days. Stool specimens were collected before, during and after ceftibuten administration. Ceftibuten was well absorbed; on average 123 mg was excreted in urine 0-6 h after dosing, while only two volunteers had detectable concentrations of ceftibuten in faeces (< or = 3.2 mg/kg). There was an overgrowth of enterococci during the administration period, while the numbers of Escherichia coli and anaerobic cocci were reduced. Six volunteers were colonized by Clostridium difficile during days 4 to 17. Beta-lactamase activity was detected in faecal samples from eight volunteers and increased significantly during the administration period.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8132366     DOI: 10.1007/bf01728916

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

Review 1.  A model of bacterial-antimicrobial interactions: the case of oropharyngeal and gastrointestinal microflora.

Authors:  C Edlund; C E Nord
Journal:  J Chemother       Date:  1991-01       Impact factor: 1.714

Review 2.  Impact of antimicrobial agents on human intestinal microflora.

Authors:  C E Nord; C Edlund
Journal:  J Chemother       Date:  1990-08       Impact factor: 1.714

3.  Influence of amoxycillin on microbial colonization resistance in healthy volunteers. A methodological study.

Authors:  E J Vollaard; H A Clasener; A J Janssen; H J Wynne
Journal:  J Antimicrob Chemother       Date:  1990-05       Impact factor: 5.790

4.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid.

Authors:  R Wise; S A Bennett; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

6.  The pharmacokinetics of ceftibuten in humans.

Authors:  W H Barr; C C Lin; E Radwanski; J Lim; S Symchowicz; M Affrime
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jan-Feb       Impact factor: 2.803

7.  Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.

Authors:  R Wise; J M Andrews; J P Ashby; D Thornber
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jan-Feb       Impact factor: 2.803

8.  Effect of phenoxymethylpenicillin and clindamycin on the oral, throat and faecal microflora of man.

Authors:  A Heimdahl; C E Nord
Journal:  Scand J Infect Dis       Date:  1979

9.  Alterations in human fecal flora, including ingrowth of Clostridium difficile, related to cefoxitin therapy.

Authors:  M E Mulligan; D Citron; E Gabay; B D Kirby; W L George; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

10.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

  10 in total
  4 in total

1.  Ceftibuten in paediatrics.

Authors:  R D Colucci; M Elliott; M B Affrime; N Zampaglione
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

2.  Clostridium difficile-associated enteric disease after percutaneous endoscopic gastrostomy.

Authors:  Shiro Yokohama; Masaru Aoshima; Toshiyuki Asama; Junya Shindo; Junichi Maruyama
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

Review 3.  Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

4.  Effects of treatment with antimicrobial agents on the human colonic microflora.

Authors:  Fatemeh Rafii; John B Sutherland; Carl E Cerniglia
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.